NeuroSense Therapeutics Ltd. NRSN
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.86M | 4.21M | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.09M | 9.66M | -- | -- | -- |
| Operating Income | -11.09M | -9.66M | -- | -- | -- |
| Income Before Tax | -11.13M | -9.72M | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.13 | -9.72 | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.13M | -9.72M | -- | -- | -- |
| EBIT | -11.09M | -9.66M | -- | -- | -- |
| EBITDA | -11.07M | -9.64M | -- | -- | -- |
| EPS Basic | -8.73 | -7.88 | -- | -- | -- |
| Normalized Basic EPS | -5.46 | -4.93 | -- | -- | -- |
| EPS Diluted | -8.73 | -7.88 | -- | -- | -- |
| Normalized Diluted EPS | -5.46 | -4.93 | -- | -- | -- |
| Average Basic Shares Outstanding | 5.10M | 4.90M | -- | -- | -- |
| Average Diluted Shares Outstanding | 5.10M | 4.90M | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |